$CRQ quantum IPO with just $58m mcap

Why Quantum Computing Is Not Optional

We are approaching the limits of what classical computers can do - not because our processors aren't fast enough, but because some problems are fundamentally too complex for binary computation to handle. Simulating how a molecule behaves, optimising a global supply chain with thousands of interdependent variables, breaking modern encryption, modelling climate systems at meaningful resolution - these are not problems you can solve by adding more transistors. The number of possible states grows exponentially, and classical computers drown. We've been papering over this ceiling for decades with clever approximations, but approximations have real costs: drugs that take 13 years and $2.6 billion to discover because we can't accurately simulate molecular interactions; financial models that misunderstand risk because they can't process correlated variables at scale; materials science that moves at a crawl because we're guessing at quantum behaviour rather than computing it.

Quantum computers don't just do the same thing faster - they represent information differently. Qubits can exist in superposition and become entangled, meaning a quantum system can hold and process exponentially more states simultaneously than any binary machine. For the specific class of problems that are quantum in nature - chemistry, cryptography, optimisation, simulation - this is not an improvement in degree. It is a change in kind. The industries that crack these problems first will have capabilities that are simply unavailable to those still running on classical hardware. That is why every major government on earth is funding quantum research, and why the race to build reliable quantum systems is one of the defining technology competitions of this decade.

On April 17, 2026, Creotech Quantum debuts on the Warsaw Stock Exchange at a book valuation of PLN 208.3 million - roughly $56 million USD at today's rate. That number will likely look quaint within a few years. Or it won't, and this will have been a speculative bet that didn't pay off. That's the honest framing. Here's the full case. Creotech Quantum splits from Creotech Instruments.

What Creotech Quantum actually builds

First, dispense with the hype. This is not a company racing to build a fault-tolerant quantum computer that will displace classical computing. That story - the IonQ story, the Rigetti story - is a decade-long bet on a technology that remains pre-commercial at scale.

Creotech Quantum is something more immediately useful: an instrumentation and systems integrator that builds the hardware that makes quantum systems work. The distinction matters enormously for the investment case, because it means the company has revenue today, working products today, and paying institutional customers today.

The business runs on four product lines.

QKD - Quantum Key Distribution. This is the most commercially urgent. Under the EU-commissioned eCAUSIS project - which Creotech leads in partnership with Austria's AIT and Germany's Fraunhofer Institute - the company has built a proprietary QKD system for ground-based fibre networks. Full IP ownership. Commercial launch targeted for 2026. The customers: EU government ministries, critical national infrastructure operators, defence institutions, and financial sector firms that need to protect communications against future quantum computers. The long-term roadmap extends to space-based QKD integrated with satellite systems.

Sinara / ARTIQ quantum computer control systems. Control electronics for trapped-ion and cold-atom quantum processors - co-developed with the University of Oxford, already adopted by leading global research laboratories. Revenue-generating today via module sales. The company is transitioning from selling individual components to delivering full integrated systems at higher margins. Two complete quantum computers are currently being built: one for the European Commission, one for the Poznań Supercomputing Center.

White Rabbit time synchronisation. Sub-nanosecond precision timing technology originally developed at CERN - where Creotech's founders trained. One of only a handful of companies globally capable of building electronics at this specification. Already commercially proven via a delivered project for Orange (France Telecom), achieving atomic-clock precision over standard fibre infrastructure. Growing commercial relevance for 5G networks, financial trading systems, and distributed sensing.

CreoSky cameras. High-sensitivity optical systems developed originally for quantum processor control, now commercialised for space debris monitoring and near-Earth object detection. First sale completed in August 2025. A telescope array prototype project is underway with German and Polish university partners, targeting the EU's Space Surveillance and Tracking network as an early customer base.

The moat no spreadsheet can model

The standard investment question is: what's the competitive advantage? For Creotech Quantum, the most durable advantage isn't technological - it's structural. It is the only European company capable of serving the EU's sovereign quantum communications mandate at the hardware level.

The EU has committed €1 billion to its Quantum Flagship programme. The explicit political objective is to build a quantum technology ecosystem independent of Chinese or American suppliers (my opinion). Creotech Quantum is the leading hardware integrator inside that ecosystem. It didn't stumble into this position - it was selected by the European Commission to lead eCAUSIS precisely because of that capability.

For QKD specifically - the protection of government communications, critical infrastructure, military systems - the idea that EU institutions will purchase Chinese or American hardware is not merely commercially unlikely. It is politically untenable. National security legislation across EU member states is increasingly mandating domestic or allied-nation sourcing for cryptographic infrastructure. This trend is accelerating, not reversing.

No amount of engineering excellence from IonQ, Toshiba Quantum, or any Chinese player can overcome that structural barrier. And the geopolitical pressure is building from multiple directions: EU strategic autonomy doctrine has hardened since 2022, and the disruption to transatlantic technology partnerships in the Trump era is pushing EU institutions further toward European supply chains.

Beyond the political positioning, Creotech Quantum's institutional relationships are themselves a moat. Its founders came from CERN. The company currently supplies electronics to CERN, ESA, DESY, and GSI - the most technically demanding research institutions in Europe. These relationships are not easily replicated. They function simultaneously as validation, as a continuous pipeline for co-funded product development, and as reference accounts that open government procurement doors.

The February 2026 partnership with Eutelsat for the EU's IRIS2 programme (via Creotech Instruments)- a €10.6 billion satellite constellation designed to provide secure EU communications - illustrates the dynamic perfectly. IRIS2 is a geopolitically-motivated infrastructure project that will require European quantum-safe communications hardware by design. Creotech Quantum is already at the table.

The valuation

At PLN 208.3M (~$56M USD), the spin-off valuation reflects the accounting value of assets transferred at a July 2025 reference date. It is not a market-clearing price - it's a floor from which price discovery begins on April 17 (maybe down?).

Consider the comparable universe. IonQ trades at approximately $4.5 billion. D-Wave at $700 million. Rigetti at $300 million. These are all US-listed, dollar-denominated, and none of them have the EU sovereign positioning that Creotech Quantum does. Even Arqit - a UK quantum-safe encryption company with barely $500K in annual revenue — has traded near $1 billion at peak.

The more grounded valuation framework: Creotech Quantum's quantum segment was generating roughly PLN 16–20M annually, with 20% year-on-year growth in the first half of 2025. The book valuation implies a revenue multiple of approximately 10–12x. For a deep-tech company with proprietary IP, EU institutional contracts, and multiple commercial product launches imminent, that is not excessive.

The critical asymmetry in this investment: downside is anchored to real assets - working products, signed contracts, institutional relationships, and a PLN 58 million grant pipeline currently under evaluation. Upside is indexed to the EU's multi-billion quantum infrastructure spending over the next decade, and to market re-rating as QKD becomes a recognised commercial category.

What needs to happen - the catalyst map

The investment resolves over a 2–4 year horizon. The near-term catalysts are already partially de-risked.

The KNF (Polish Financial Supervision Authority) approved the prospectus on February 18, 2026. The Eutelsat/IRIS2 partnership was signed the same month. The legal and institutional groundwork is complete. April 2 is the record date for CRI shareholders to receive CRQ shares; April 17 is the debut (for holding CRI, there will be a CRQ airdrop).

From there: commercial QKD product launch in H2 2026; EU quantum computer delivery milestones in 2026–2027; resolution of the PLN 58M grant pipeline in H1 2026; and the longer-dated integration of QKD systems with Creotech Instruments' HyperSat satellite platform - a combination that would create a space-ground quantum secure communications capability with no European equivalent.

The risks

This is a pre-scale deep-tech company. The risks are real.

Commercialisation can slip. QKD systems require government certification, and procurement timelines in EU member states are slow. The PLN 100M cumulative revenue target for 2026–2028 is ambitious, and a meaningful portion of it depends on grant income alongside commercial contracts.

Dilution is likely. Creotech Quantum enters the market without fresh capital from the spin-off. Future equity raises are probable as the company scales. Investors should price that in.

Technical execution risk is real. The second-generation QKD module is still in final testing. Prototype-to-production is a genuine engineering challenge at these specifications.

Liquidity will be thin. With 2.85 million shares outstanding and a small-cap valuation, this is not a stock you can exit quickly in size. It will be volatile. It requires patience. Might be hard to get filled close to the IPO price. We might never see those levels again. I have CRI exposure, so I will get some CRQ stocks, but I haven't figured out an exact play yet.

https://docs.google.com/spreadsheets/d/1_2zSApV-ei2dRZdtpAbSN-fI4f1nadXOIb-7d6P9WW8/edit?gid=1204099566#gid=1204099566